Cancer Stem Cell News Volume 3.29 | Jul 30 2014

Cancer Stem Cell News 3.29 July 30, 2014

Cancer Stem Cell News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CSCN on Twitter

DNA-Damage-Induced Differentiation of Leukemic Cells as an Anti-Cancer Barrier
Researchers show that the histone methyl-transferase MLL4, a suppressor of B-cell lymphoma is required for stem-cell activity and an aggressive form of acute myeloid leukemia harboring the MLL-AF9 oncogene. [Nature] Abstract
NeuroCult™ for Brain Tumor Research - View Publications

PUBLICATIONS (Ranked by impact factor of the journal)
Epigenetic Targeting of Ovarian Cancer Stem Cells
Researchers demonstrate that aldehyde dehydrogenase+ ovarian cancer cells possess multiple stem cell characteristics, are highly chemoresistant, and are enriched in xenografts residual after platinum therapy. [Cancer Res] Abstract

Endothelial Interleukin-6 Defines the Tumorigenic Potential of Primary Human Cancer Stem Cells
Researchers report that stromal interleukin (IL)-6 defines the tumorigenic capacity of cancer stem cells (CSC) sorted from primary human head and neck squamous cell carcinomas and transplanted into mice. In search for the cellular source of IL-6, they observed a direct correlation between IL-6 levels in tumor-associated endothelial cells and the tumorigenicity of CSC. [Stem Cells] Abstract

miR-7, Inhibited Indirectly by LincRNA HOTAIR, Directly Inhibits SETDB1 and Reverses the EMT of Breast Cancer Stem Cells by Downregulating the STAT3 Pathway
Investigators show that microRNA-7 (miR-7), which was downregulated in breast cancer stem cells (BCSCs) isolated from the human MCF-7 and MDA-MB-231 cell lines, inhibited cell invasion and metastasis, decreased the BCSC population and partially reversed epithelial-mesenchymal transition (EMT) in MDA-MB-231 cells by directly targeting the oncogene, SETDB1. [Stem Cells] Abstract

Nestin Positively Regulates the Wnt/β-Catenin Pathway and the Proliferation, Survival, and Invasiveness of Breast Cancer Stem Cells
Researchers investigated Nestin expression in triple-negative breast cancer and examined how the modulation of Nestin expression affects cell cycle progression, survival, invasion and regulatory signaling in breast cancer stem cells in vitro. [Breast Cancer Res] Abstract | Full Article

Selective Release of a Cyclopamine Glucuronide Prodrug towards Stem-Like Cancer Cell Inhibition in Glioblastoma
Scientists tested a derivatization product of cyclopamine in the form of cyclopamine glucuronide prodrug. This compound was used in vitro and in vivo toward glioblastoma-initiating cells. [Mol Cancer Ther] Abstract

Enhanced Photodynamic Therapy and Effective Elimination of Cancer Stem Cells Using Surfactant-Polymer Nanoparticles
Investigators found that nanoparticle encapsulated methylene blue has the capacity to eliminate cancer stem cells under hypoxic conditions. [Mol Pharm] Abstract

Resveratrol Inhibits Breast Cancer Stem-Like Cells and Induces Autophagy via Suppressing Wnt/β-Catenin Signaling Pathway
Scientists investigated the effects of resveratrol on breast cancer stem cells (CSCs). Resveratrol significantly inhibits the proliferation of breast CSCs (BCSCs) isolated from MCF-7 and SUM159, and decreased the percentage of BCSCs population, consequently reduced the size and number of mammospheres in non-adherent spherical clusters. [PLoS One] Full Article

Reprogramming Ovarian and Breast Cancer Cells into Non-Cancerous Cells by Low-Dose Metformin or SN-38 through FOXO3 Activation
Scientists show that low-dose metformin or SN-38 inhibits cell growth or survival in ovarian and breast cancer cells and suppresses their tumor growth in vivo. Low-dose metformin or SN-38 increases FOXO3 nuclear localization as well as the amount of DNA damage markers and downregulates the expression of a cancer-stemness marker CD44 and other stemness markers, including Nanog, Oct-4, and c-Myc, in these cancer cells. [Sci Rep] Full Article

Culture and Characterize Mouse Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Mouse) - Free Protocols

The Emerging Role of Tumor-Suppressive MicroRNA-218 in Targeting Glioblastoma Stemness
An accumulating body of evidence shows that microRNA-218 (miR-218) may act as a tumor suppressor by inhibiting glioblastoma invasion, migration, proliferation and stemness through its different targets, indicating the great potential and relevance of miR-218 as a novel class of therapeutic target in glioblastoma. [Cancer Lett] Abstract

Cancer Stem Cell Detection and Isolation
Considering cancer stem cells (CSCs) involvement in tumor relapse and chemotherapeutic resistance, identification of such cells in tumors is imperative for effective targeted therapy. The authors introduce practical and specific protocols used to isolate CSCs from solid tumors from colon, esophagus, liver, breast, brain, and cervix. [Med Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Baylor Sammons Cancer Center Joins Actinium Pharmaceuticals, Inc. as Clinical Trial Site for Actinium’s Actimab-A Clinical Trial
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. [Actinium Pharmaceuticals, Inc. (Business Wire)] Press Release

Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies
Incyte Corporation announced that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 inhibitor, INCB24360, in combination with Genentech’s PD-L1 immune checkpoint inhibitor, MPDL3280A, in patients with non-small cell lung cancer. [Incyte Corporation] Press Release

Novogen and CanTx Appoint Contract Manufacturers to Produce Clinical Batches of Cantrixil®
Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd. announced that they have named two key contract manufacturing organizations to produce clinical batches of the experimental anti-cancer drug, Cantrixil™. [Novogen Ltd.] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration).
Request your free copy.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW FAST: Functional Analysis & Screening Technologies Congress
November 17-19, 2014
Boston, United States

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW PhD Student – Cancer Stem Cells (KU Leuven)

Technical Account Manager (GlobalStem)

Postdoctoral Position – Molecular Properties of Leukemic Stem Cells (BC Cancer Agency)

Postdoctoral Fellow – Genome Editing in Human Embryonic Stem Cells to Study Hereditary Cancer-Associated Mutations (UConn Health Center)

PhD Candidate – Mammary Stem Cell Biology (University of Amsterdam)

Postdoctoral Research Associate – Cancer Stem Cell Biology (University of California, San Diego)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Research Assistant/Research Associate – Stem Cell and Cancer Biology (University of North Texas Health Science Center)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine in New York)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us